Cancer is traditionally described as a disease caused by uncontrolled proliferation of genetically abnormal cells. However, malignant cells do not develop or function in isolation. They exist within a highly dynamic tissue environment containing multiple types of normal and abnormal cells, extracellular matrix proteins, blood vessels, soluble signaling molecules, and physical conditions that influence tumor behavior. This surrounding environment is commonly referred to as the tumor microenvironment.

The tumor microenvironment is now recognized as an important component of cancer biology. Communication between cancer cells and surrounding stromal and immune cells can influence almost every stage of tumor development. Signals originating from the microenvironment can promote cancer-cell proliferation, survival, invasion, angiogenesis, immune escape, and metastatic dissemination. Conversely, cancer cells actively modify their surrounding environment by releasing growth factors, cytokines, extracellular vesicles, and metabolic products.

The composition of the tumor microenvironment varies between tumor types and even between different regions of the same tumor. A breast tumor, for example, may contain different cellular populations and extracellular matrix characteristics from a pancreatic or colorectal tumor. Even within one tumor, areas close to blood vessels may differ substantially from hypoxic or necrotic regions.

This heterogeneity makes the tumor microenvironment both biologically complex and therapeutically important. Treatment approaches directed exclusively against cancer cells may be insufficient when surrounding stromal cells continue to provide survival signals. Consequently, modern cancer research increasingly considers the tumor microenvironment as a potential therapeutic target.

Cellular and Molecular Components of the Tumor Microenvironment

The tumor microenvironment consists of numerous interacting components. Cancer-associated fibroblasts, immune cells, endothelial cells, pericytes, mesenchymal stromal cells, extracellular matrix proteins, and soluble mediators form an interconnected system around malignant cells.

Cancer-associated fibroblasts are particularly important stromal cells. They can produce extracellular matrix proteins and release growth factors, cytokines, and chemokines. Through these activities, they can modify tissue structure and stimulate tumor-cell survival and migration. Fibroblasts can also contribute to therapeutic resistance by creating physical and biochemical barriers to drug penetration.

Immune cells represent another major component. These include macrophages, neutrophils, lymphocytes, dendritic cells, natural killer cells, and regulatory T cells. Although immune cells can recognize and destroy malignant cells, tumors can modify immune responses to create an immunosuppressive environment.

Endothelial cells form the vascular component of the microenvironment. Tumors require new blood vessels to sustain continued growth beyond a limited size. Tumor-associated angiogenesis also provides routes through which cancer cells can enter the circulation and disseminate to distant organs.

The extracellular matrix provides structural support but also functions as a signaling platform. Collagen, fibronectin, laminins, proteoglycans, and other matrix components interact with cell-surface receptors and influence cell adhesion, migration, proliferation, and survival.

Cancer-Associated Fibroblasts and Tumor Progression

Cancer-associated fibroblasts are among the most influential stromal populations within many solid tumors. They differ from normal fibroblasts in their phenotype, activity, and interactions with malignant cells. CAFs can be activated by signals released from cancer cells and other components of the tumor microenvironment.

Activated fibroblasts can release transforming growth factor-β, hepatocyte growth factor, fibroblast growth factors, interleukins, and other mediators. These signals can stimulate tumor-cell proliferation and survival. CAFs also remodel the extracellular matrix by producing and modifying collagen and other structural proteins.

Excessive matrix deposition can increase tissue stiffness. Mechanical changes in the tumor environment can activate mechanosensitive pathways in cancer cells and promote invasive behavior. Increased matrix stiffness can also influence blood-vessel formation and immune-cell infiltration.

CAFs may therefore function as biological and physical regulators of tumor progression rather than simply supporting tissue structure.

Immune Cells and Immune Evasion

The immune system has the ability to recognize abnormal cells and eliminate them. Nevertheless, advanced tumors frequently develop mechanisms that suppress antitumor immune responses.

Tumor-associated macrophages can exist in different functional states depending on the signals present in their environment. Certain macrophage populations can produce inflammatory mediators and contribute to tumor destruction, whereas others can promote angiogenesis, tissue remodeling, immune suppression, and tumor growth.

Regulatory T cells can suppress immune responses against tumor cells. Myeloid-derived suppressor cells can also inhibit T-cell and natural killer-cell activity.

Tumors can additionally express immune checkpoint molecules that reduce immune-cell activation. The interaction between programmed death ligand 1 and programmed death 1 is one important example.

These mechanisms can create an immunosuppressive environment that allows malignant cells to evade immune destruction.

Hypoxia and Metabolic Changes

Rapid tumor growth can outpace the development of an adequate blood supply. As a consequence, many tumors contain regions with low oxygen availability.

Hypoxia activates hypoxia-inducible factors that regulate genes involved in metabolism, angiogenesis, survival, and adaptation. These changes allow tumor cells to survive under oxygen-limited conditions.

Hypoxic cancer cells can alter glucose metabolism and increase glycolytic activity. The resulting metabolic changes can influence the surrounding environment by increasing lactate production and altering extracellular acidity.

Acidic conditions can affect immune-cell activity, extracellular matrix remodeling, and cancer-cell migration.

Thus, hypoxia and altered metabolism create a microenvironment that can support tumor progression.

Angiogenesis

Tumors require blood vessels to supply oxygen and nutrients and to remove metabolic waste. Cancer cells and stromal cells can release vascular endothelial growth factor and other angiogenic mediators.

New tumor-associated vessels are often structurally abnormal. They may be irregular, leaky, and poorly organized.

Abnormal vasculature can create uneven oxygen delivery and contribute to areas of hypoxia.

At the same time, the abnormal vascular network provides opportunities for cancer cells to enter the bloodstream.

Angiogenesis therefore contributes to both tumor growth and metastatic dissemination.

Extracellular Matrix Remodeling

The extracellular matrix undergoes substantial changes during tumor progression.

Cancer cells and stromal cells can increase production of collagen, fibronectin, laminins, and other matrix components. Matrix-remodeling enzymes, including matrix metalloproteinases, can modify the extracellular environment.

These changes can create pathways that facilitate cancer-cell invasion.

The extracellular matrix can also store growth factors and release them during remodeling.

Integrin-mediated signaling connects extracellular matrix changes with intracellular pathways regulating proliferation and survival.

Consequently, matrix remodeling is an active component of tumor progression rather than merely a structural alteration.

Figure 1. Major Interactions Within the Tumor Microenvironment

                         TUMOR MICROENVIRONMENT

                                  │

          ┌───────────────────────┼────────────────────────┐

          │                       │                        │

          ▼                       ▼                        ▼

   Cancer Cells            Immune Cells              Stromal Cells

          │                 │     │     │                   │

          │                 ▼     ▼     ▼                   ▼

          │              T cells  TAMs  MDSCs              CAFs

          │                 │     │     │                   │

          └─────────────────┼─────┼─────┼───────────────────┘

                            ▼     ▼     ▼

                     Cytokines / Chemokines

                            │

          ┌─────────────────┼─────────────────┐

          ▼                 ▼                 ▼

      Angiogenesis       ECM Remodeling     Immune Suppression

          │                 │                 │

          └─────────────────┼─────────────────┘

                            ▼

                    Tumor Progression

                            │

             ┌──────────────┼──────────────┐

             ▼              ▼              ▼

          Invasion      Metastasis      Resistance

Figure 1: Major cellular and molecular interactions within the tumor microenvironment that contribute to cancer progression, metastasis, immune suppression, and therapeutic resistance.

Tumor Microenvironment and Metastasis

Metastasis requires cancer cells to detach from the primary tumor, invade surrounding tissue, enter the circulation, survive during transport, exit blood vessels, and establish growth at distant sites.

The tumor microenvironment contributes to several of these steps.

Matrix remodeling facilitates local invasion, while angiogenesis provides access to blood vessels. Stromal and immune cells can release signals that enhance cancer-cell migration and survival.

Cancer cells can also modify distant tissues before their arrival by releasing extracellular vesicles and other factors. These changes may contribute to the development of a pre-metastatic niche.

The successful establishment of metastases therefore depends not only on the characteristics of cancer cells but also on the compatibility of the surrounding tissue environment.

Extracellular Vesicles and Cell-to-Cell Communication

Extracellular vesicles provide an important mechanism of communication between cancer cells and surrounding cells.

They can carry proteins, lipids, messenger RNAs, microRNAs, and other molecular components.

Tumor-derived extracellular vesicles can modify fibroblasts, immune cells, endothelial cells, and distant tissues.

Through this mechanism, cancer cells can influence their microenvironment without direct physical contact.

Extracellular vesicles may also participate in drug resistance by transferring molecules associated with survival and treatment adaptation.

Tumor Microenvironment and Therapeutic Resistance

The tumor microenvironment can substantially reduce the effectiveness of anticancer treatment.

Dense extracellular matrix can restrict drug diffusion.

Abnormal blood vessels can produce uneven drug delivery.

Hypoxic regions may contain slowly proliferating cells that are less sensitive to certain chemotherapeutic agents.

Stromal cells can release survival signals that protect cancer cells from treatment-induced apoptosis.

Immune suppression can also reduce the effectiveness of immune-based therapies.

Consequently, therapeutic resistance may arise from interactions between cancer cells and their surrounding environment rather than from cancer-cell-intrinsic mechanisms alone.

Review Design

The present article was prepared as a narrative review examining the role of the tumor microenvironment in cancer progression.

Literature Search

Relevant scientific literature was considered from major biomedical databases and peer-reviewed journals.

Search terms included combinations of:

“tumor microenvironment,” “cancer progression,” “cancer-associated fibroblasts,” “tumor-associated macrophages,” “angiogenesis,” “hypoxia,” “extracellular matrix,” “immune evasion,” “metastasis,” “extracellular vesicles,” and “therapeutic resistance.”

Inclusion Criteria

Studies investigating interactions between malignant cells and the tumor microenvironment were considered relevant.

Particular attention was given to research addressing stromal cells, immune cells, extracellular matrix, hypoxia, angiogenesis, metabolic changes, metastasis, and treatment resistance.

Data Synthesis

The available evidence was organized according to major cellular components and their roles in tumor growth, invasion, immune regulation, metastasis, and therapeutic response.

Results

The reviewed evidence indicates that the tumor microenvironment plays an active role throughout cancer development.

Cancer-associated fibroblasts contribute to extracellular matrix remodeling and release signaling molecules that support tumor-cell survival.

Immune-cell populations can either suppress or promote tumor growth depending on their functional state.

Tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells can contribute to immune suppression.

Hypoxia activates adaptive pathways that promote angiogenesis and metabolic reprogramming.

Extracellular matrix remodeling increases tissue stiffness and facilitates invasion.

Abnormal blood vessels contribute to tumor growth, hypoxia, and metastatic dissemination.

These microenvironmental factors can interact with one another and collectively promote tumor progression and treatment resistance.

The tumor microenvironment has emerged as one of the most important regulators of cancer biology.

Although genetic alterations within cancer cells remain central to tumor development, the behavior of malignant cells is strongly influenced by surrounding tissues.

One of the most important characteristics of the tumor microenvironment is its dynamic nature.

Cancer cells continuously release molecules that modify surrounding cells, while stromal and immune cells respond by producing additional signals.

This creates a feedback system that can progressively favor tumor growth.

Cancer-associated fibroblasts provide an important example of this process.

They can remodel the extracellular matrix and release growth factors that promote malignant-cell survival.

The resulting changes in tissue stiffness can activate signaling pathways that increase invasion.

Immune cells demonstrate another important aspect of microenvironmental regulation.

The immune system can initially recognize and eliminate abnormal cells, but persistent tumor-associated signaling can lead to an immunosuppressive environment.

Macrophages, regulatory T cells, and myeloid-derived suppressor cells can inhibit effective antitumor immunity.

Hypoxia further increases microenvironmental complexity.

Low oxygen availability activates transcriptional programs that promote angiogenesis and metabolic adaptation.

However, the resulting vessels are frequently abnormal, leading to continued regions of hypoxia.

This creates a self-reinforcing cycle of poor perfusion, metabolic stress, and tumor adaptation.

The extracellular matrix is similarly dynamic.

Increased collagen deposition and matrix crosslinking can alter tissue mechanics.

These mechanical changes can influence integrin signaling and promote cancer-cell migration.

Matrix remodeling can also facilitate access to blood vessels and support metastatic dissemination.

The tumor microenvironment therefore contributes to cancer progression through multiple interconnected mechanisms rather than through one isolated pathway.

Therapeutic Targeting of the Tumor Microenvironment

Because the tumor microenvironment contributes to tumor progression, targeting its components may complement conventional anticancer treatment.

Potential strategies include inhibition of angiogenic signaling, modulation of cancer-associated fibroblasts, reprogramming of tumor-associated macrophages, disruption of extracellular matrix interactions, and targeting of immunosuppressive pathways.

Anti-angiogenic therapies aim to reduce abnormal blood-vessel formation.

Immune checkpoint inhibitors can restore antitumor immune responses in appropriate tumor settings.

Strategies targeting fibroblast-associated signaling are also being investigated.

However, microenvironment-directed therapy requires careful consideration because many stromal components are also present in normal tissues.

Future Perspectives

Future research should focus on understanding the spatial and temporal heterogeneity of the tumor microenvironment.

Single-cell sequencing can identify distinct cellular populations, while spatial transcriptomic approaches can determine where specific molecular interactions occur within tumors.

Advanced imaging technologies may provide additional information about blood flow, oxygen levels, extracellular matrix organization, and immune-cell distribution.

Another promising direction is the development of combination treatments targeting both malignant cells and supportive microenvironmental components.

For example, molecularly targeted therapy could potentially be combined with immune modulation or strategies that improve drug penetration.

The integration of molecular profiling with microenvironmental information may ultimately improve patient selection and treatment outcomes.

The tumor microenvironment is an active and dynamic component of cancer progression.

Cancer-associated fibroblasts, immune cells, endothelial cells, extracellular matrix components, and soluble signaling molecules interact continuously with malignant cells.

These interactions regulate tumor growth, angiogenesis, invasion, metastasis, immune evasion, metabolic adaptation, and therapeutic resistance.

Hypoxia and abnormal vascularization create additional conditions that promote tumor survival and progression.

The extracellular matrix provides both structural support and biochemical signals that influence cancer-cell behavior.

Understanding these complex interactions has important implications for cancer therapy.

Future treatment strategies may increasingly combine direct targeting of malignant cells with interventions designed to modify the tumor microenvironment.

A more comprehensive understanding of tumor–stroma interactions, supported by single-cell and spatial technologies, may facilitate the development of more effective and personalized cancer treatments.

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
2. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discovery. 2022;12:31–46.
3. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature Medicine. 2013;19:1423–1437.
4. Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348:74–80.
5. Kalluri R. The biology and function of fibroblasts in cancer. Nature Reviews Cancer. 2016;16:582–598.
6. Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. Journal of Experimental Medicine. 2014;211:1503–1523.
7. Quail DF, Joyce JA. Cancer: fibroblasts take centre stage. Nature Reviews Cancer. 2013;13:742–752.
8. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nature Reviews Clinical Oncology. 2017;14:399–416.
9. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61.
10. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment. Nature Medicine. 2018;24:541–550.
11. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257.
12. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer and Metastasis Reviews. 2007;26:225–239.
13. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nature Reviews Cancer. 2009;9:239–252.
14. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309–322.
15. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nature Reviews Cancer. 2006;6:392–401.
16. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Research. 2019;79:4557–4566.
17. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904–5912.
18. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment. Nature Medicine. 2018;24:541–550.
19. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018. Journal of Extracellular Vesicles. 2018;7:1535750.
20. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367:eaau6977.